Bluebird Bio Stock Buy Hold or Sell Recommendation
| BLUE Stock | USD 0.35 0.05 16.67% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Bluebird bio is 'Strong Sell'. Macroaxis provides Bluebird Bio buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding BLUE positions.
Check out Bluebird Bio Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Bluebird Stock refer to our How to Trade Bluebird Stock guide. Note, we conduct extensive research on individual companies such as Bluebird and provide practical buy, sell, or hold advice based on investors' constraints. Bluebird bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
Bluebird |
Execute Bluebird Bio Buy or Sell Advice
The Bluebird recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Bluebird bio. Macroaxis does not own or have any residual interests in Bluebird bio or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Bluebird Bio's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Very Weak | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Bluebird Bio Trading Alerts and Improvement Suggestions
| Bluebird bio generated a negative expected return over the last 90 days | |
| Bluebird bio has high historical volatility and very poor performance | |
| Bluebird bio has some characteristics of a very speculative penny stock | |
| Bluebird bio has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 29.5 M. Net Loss for the year was (211.91 M) with loss before overhead, payroll, taxes, and interest of (247.24 M). | |
| Bluebird bio currently holds about 132.51 M in cash with (235.05 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.72, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Bluebird bio has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from investing.com: Bluebird Bios SWOT analysis gene therapy firm faces cash crunch amid launch |
Bluebird Bio Returns Distribution Density
The distribution of Bluebird Bio's historical returns is an attempt to chart the uncertainty of Bluebird Bio's future price movements. The chart of the probability distribution of Bluebird Bio daily returns describes the distribution of returns around its average expected value. We use Bluebird bio price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Bluebird Bio returns is essential to provide solid investment advice for Bluebird Bio.
| Mean Return | -0.86 | Value At Risk | -10 | Potential Upside | 7.02 | Standard Deviation | 5.27 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Bluebird Bio historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Bluebird Stock Institutional Investors
| Shares | Exoduspoint Capital Management, Lp | 2024-09-30 | 1.3 M | Bank Of America Corp | 2024-06-30 | 1.3 M | Deutsche Bank Ag | 2024-06-30 | 1.2 M | Jane Street Group Llc | 2024-06-30 | 1.1 M | Renaissance Technologies Corp | 2024-09-30 | 1.1 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1 M | Masters Capital Management Llc | 2024-09-30 | 975 K | Woodline Partners Lp | 2024-06-30 | 969.3 K | Susquehanna International Group, Llp | 2024-06-30 | 901.9 K | Blackrock Inc | 2024-06-30 | 15.4 M | Vanguard Group Inc | 2024-09-30 | 10.5 M |
Bluebird Bio Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (35.4M) | (8.0M) | (167.0M) | (48.2M) | 116.2M | 122.0M | |
| Free Cash Flow | (640.6M) | (499.3M) | (658.6M) | (366.2M) | (244.1M) | (256.3M) | |
| Depreciation | 17.4M | 19.4M | 19.6M | 5.0M | 28.5M | 30.0M | |
| Other Non Cash Items | (8.3M) | (6.0M) | 17.6M | (87.4M) | (36.9M) | (35.1M) | |
| Capital Expenditures | 76.3M | 29.0M | 23.0M | 13.2M | 9.1M | 8.6M | |
| Net Income | (789.6M) | (618.7M) | (819.4M) | (266.6M) | (211.9M) | (222.5M) | |
| End Period Cash Flow | 381.7M | 373.7M | 206.7M | 158.4M | 274.6M | 309.7M | |
| Change To Netincome | 149.6M | 150.6M | 146.1M | (52.3M) | (60.1M) | (57.1M) | |
| Investments | 584.1M | (55.4M) | 475.3M | 250.5M | 155.0M | 162.7M |
Bluebird Bio Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Bluebird Bio or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Bluebird Bio's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Bluebird stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -1.1 | |
β | Beta against Dow Jones | 1.92 | |
σ | Overall volatility | 5.21 | |
Ir | Information ratio | -0.19 |
Bluebird Bio Volatility Alert
Bluebird bio exhibits very low volatility with skewness of 0.09 and kurtosis of 1.49. Bluebird bio is a potential penny stock. Although Bluebird Bio may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Bluebird bio. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Bluebird instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Bluebird Bio Fundamentals Vs Peers
Comparing Bluebird Bio's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Bluebird Bio's direct or indirect competition across all of the common fundamentals between Bluebird Bio and the related equities. This way, we can detect undervalued stocks with similar characteristics as Bluebird Bio or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Bluebird Bio's fundamental indicators could also be used in its relative valuation, which is a method of valuing Bluebird Bio by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Bluebird Bio to competition |
| Fundamentals | Bluebird Bio | Peer Average |
| Return On Equity | -1.87 | -0.31 |
| Return On Asset | -0.36 | -0.14 |
| Operating Margin | (5.49) % | (5.51) % |
| Current Valuation | 365.83 M | 16.62 B |
| Shares Outstanding | 194.44 M | 571.82 M |
| Shares Owned By Insiders | 0.63 % | 10.09 % |
| Shares Owned By Institutions | 43.68 % | 39.21 % |
| Number Of Shares Shorted | 47.71 M | 4.71 M |
| Price To Earning | (19.32) X | 28.72 X |
| Price To Book | 0.73 X | 9.51 X |
| Price To Sales | 1.24 X | 11.42 X |
| Revenue | 29.5 M | 9.43 B |
| Gross Profit | (247.24 M) | 27.38 B |
| EBITDA | (302.11 M) | 3.9 B |
| Net Income | (211.91 M) | 570.98 M |
| Cash And Equivalents | 132.51 M | 2.7 B |
| Cash Per Share | 1.72 X | 5.01 X |
| Total Debt | 424.62 M | 5.32 B |
| Debt To Equity | 1.63 % | 48.70 % |
| Current Ratio | 1.12 X | 2.16 X |
| Book Value Per Share | 1.01 X | 1.93 K |
| Cash Flow From Operations | (235.05 M) | 971.22 M |
| Short Ratio | 9.53 X | 4.00 X |
| Earnings Per Share | (1.80) X | 3.12 X |
| Price To Earnings To Growth | 0.32 X | 4.89 X |
| Target Price | 2.36 | |
| Number Of Employees | 375 | 18.84 K |
| Beta | 0.8 | -0.15 |
| Market Capitalization | 68.07 M | 19.03 B |
| Total Asset | 619.16 M | 29.47 B |
| Retained Earnings | (4.26 B) | 9.33 B |
| Working Capital | 81.57 M | 1.48 B |
| Current Asset | 523.97 M | 9.34 B |
Note: Disposition of 2343 shares by Colvin Richard A of Bluebird Bio at 2.9769 subject to Rule 16b-3 [view details]
Bluebird Bio Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Bluebird . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Bluebird Bio Buy or Sell Advice
When is the right time to buy or sell Bluebird bio? Buying financial instruments such as Bluebird Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Bluebird Bio in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Medical Equipment Thematic Idea Now
Medical Equipment
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Medical Equipment theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Medical Equipment Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Bluebird Bio Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Bluebird Stock refer to our How to Trade Bluebird Stock guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bluebird Bio. If investors know Bluebird will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bluebird Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.80) | Revenue Per Share 0.357 | Quarterly Revenue Growth 1.337 | Return On Assets (0.36) | Return On Equity (1.87) |
The market value of Bluebird bio is measured differently than its book value, which is the value of Bluebird that is recorded on the company's balance sheet. Investors also form their own opinion of Bluebird Bio's value that differs from its market value or its book value, called intrinsic value, which is Bluebird Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bluebird Bio's market value can be influenced by many factors that don't directly affect Bluebird Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bluebird Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bluebird Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bluebird Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.